Zealand Pharma Announces Positive Phase 1A Topline Results With Kv1.3 Channel Blocker Zp9830
ReutersFeb 18, 2026 6:36 AM
Feb 18 (Reuters) - Zealand Pharma A/S ZELA.CO:
ANNOUNCES POSITIVE PHASE 1A TOPLINE RESULTS WITH KV1.3 CHANNEL BLOCKER ZP9830
ZP9830 WAS WELL TOLERATED IN THIS SINGLE ASCENDING DOSE TRIAL, WITH NO DOSE-LIMITING SAFETY FINDINGS OR OTHER SAFETY CONCERNS OBSERVED
Further company coverage: ZELA.CO
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
AMD Stock Price Prediction 2030: Can AMD Narrow Nvidia’s AI Lead?
TradingKey - In the past couple of years, the semiconductor industry has experienced a major change. One question that investors still have is whether or not AMD (AMD) will be able to keep up with Nvidia (NVDA) as far as AI is concerned. What is the possible future of AMD's stock through 2026 and beTradingKey
5 hours ago
Bitcoin Price Prediction 2029-2035: Institutional Accumulation and the U.S. Treasury’s Strategic Reserve Pivot
Explore the 2026 Bitcoin landscape: From the U.S. Strategic Reserve and Michael Saylor’s $75B war chest to Cathie Wood’s 2030 forecast. Is BTC the new Digital Gold?TradingKey
Fri, Feb 13
This $1 Trillion AI Stock Is Getting Ready for 2026: Is Meta a Good Buy?
When ads and commerce are factored in, Meta is building a long-term platform—in Augmented Reality and smart glasses — to get us closer to the future of AI. This device hardware business is less profitable than ads right now, but it could grow the company’s ecosystem and open up new ways for it to maTradingKey
Thu, Feb 12
